Nexturn has acquired 1 company, including 1 in the last 5 years.
Nexturn has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
121 Beon-Gil 35, Giheundanji-Ro Giheung-Gu,
Yongin-Si,
446-901
South Korea,
+82 3 1288 2088
www.nexturn.co.kr
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2021-05-30 |
RosVivo Therapeutics · Life Science
Reno, Nevada · www.rosvivo.com RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. Discovery research conducted by Dr. Seungil Ro’s laboratory recently identified key miRNAs responsible for the onset and development of Type 2 Diabetes (T2D). Preclinical studies show depletion of these key miRNAs leads to the development of not only T2D, but also obesity, fatty acid liver disease, hyperlipidemia, and gastroparesis. Remarkably, restoration of these miRNAs reverses these disease states. RosVivo Therapeutics is unique in that the miRNA drugs are developed will help rescue several metabolic disease states not just alleviate symptoms. RosVivo Therapeutics is based in Reno, Nevada. |
- | Stake Purchase | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
